<DOC>
	<DOCNO>NCT01007526</DOCNO>
	<brief_summary>This study evaluate efficacy risk-adapted treatment strategy stage I/II extranodal NK/T cell lymphoma . The risk stratification base Korean NK prognostic index . Thus , group I/II receive concomitant chemoradiation follow VIDL chemotherapy . The group III/IV receive high dose-chemotherapy follow autologous stem cell transplantation completion VIDL chemotherapy .</brief_summary>
	<brief_title>Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy NK/T-cell Lymphoma</brief_title>
	<detailed_description>1 . Concomitant chemo-radiotherapy : Radiotherapy 36-44 Gy/18-22 fraction + weekly cisplatin 30 mg/m2 4 week 2 . Rest period : 3 week 3 . VIDL combination chemotherapy : ( total 2 cycle ) VP-16 ( etoposide ) 100mg/m2 I.V . D1-3 Ifosfamide 1.2g/m2 I.V . D1-3 Dexamethasone 40mg/day D1-3 L-asparaginase 4000IU/m2 IM D8 , 10 , 12 , 14 , 16 , 18 , 20 Repeated every 28 day 4 . Peripheral blood stem cell mobilization G-CSF 400ug/m2/day 10ug/kg/day S.C. I.V . 4-6 day follow stem cell collection ( Minimum requirement CD34+ cell &gt; 2Ã—106/kg ) 5 . High-dose chemotherapy autologous stem cell transplantation Busulfex 3.2mg/kg/day day -7 day -5 Etoposide 400mg/m2/day day -5 , -4 Cyclophosphamide 50mg/kg/day day -3 , -2 Followed stem cell infusion</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>patient require biopsyproven diagnosis nasal ENKTL least 18 year old Ann Arbor stage IE IIE measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 life expectancy great 12 week adequate hematologic ( hemoglobin &gt; 9.0 g/dL , absolute neutrophil count &gt; 1,500/uL platelet &gt; 100,000/uL ) renal ( serum creatinine &lt; 1.5 mg/dL , creatinine clearance &gt; 50 mL/min ) hepatic ( total bilirubin &lt; 2 time upper limit normal aspartate transferase &lt; 3 time upper limit normal ) function Diagnosis ENKTL base presence histological feature immunophenotypes compatible ENKTL ( e.g. , cytoplasmic CD3+ , CD20 , CD56+ , positive cytotoxic molecule , positive EBV situ hybridization ) . Informed consent prior concomitant malignant tumor coexist medical problem sufficient severity prevent full compliance study protocol . ENKTL nonnasal site skin gastrointestinal tract exclude even localize . Other subtypes nonHodgkin lymphoma ( NHL ) , include myeloid/NK cell precursor acute leukemia , blastic NK cell lymphoma/precursor NK cell lymphoblastic leukemia , aggressive NK cell leukemia , peripheral T cell lymphoma , unspecified , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Extranodal Lymphoma</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>T cell</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>